IDENTITY AND ROLE OF NOVEL GI PEPTIDES IN HOST DEFENSE

Information

  • Research Project
  • 3495879
  • ApplicationId
    3495879
  • Core Project Number
    R43DK041947
  • Full Project Number
    1R43DK041947-01
  • Serial Number
    41947
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/1/1989 - 35 years ago
  • Project End Date
    2/28/1990 - 35 years ago
  • Program Officer Name
  • Budget Start Date
    9/1/1989 - 35 years ago
  • Budget End Date
    2/28/1990 - 35 years ago
  • Fiscal Year
    1989
  • Support Year
    1
  • Suffix
  • Award Notice Date
    8/29/1989 - 35 years ago
Organizations

IDENTITY AND ROLE OF NOVEL GI PEPTIDES IN HOST DEFENSE

Long-range objectives are (1) to identify novel drug candidates related to magainin class of peptides with potential antibacterial, antiviral and anti-inflammatory activity that have GI-related applications, and (2) advance our knowledge of the role and mechanisms of endogenous membrane channel forming peptides. Zasloff described the magainins, 21-27 amino acid peptides isolated from frog skin, with remarkable antibacterial, antifungal, and antiparasitic activities. These biologically active peptides are a noel vertebrate host defense system, acting by membrane ion channel forming mechanisms. New immunological evidence from our labs suggest the margainins are widely present in the frog's GI tract, pointing to their role in GI function and the potential of novel GI therapeutics. Our specific aim is to map the mammalian GI tract for magainin-like peptides. We will use antibodies to specific peptides to detect structurally related molecules and sensitive anti-microbial bioassays to guide purification and aid discovery of novel molecules. Isolated peptides will be sequenced and synthetic peptides made to confirm authenticity and biological testing expanded. Proposed studies can lead to major advances in understanding magainin compounds and open new approaches to GI therapeutics and host defense.

IC Name
NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
  • Activity
    R43
  • Administering IC
    DK
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    847
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    SSS
  • Study Section Name
  • Organization Name
    GENAERA CORPORATION
  • Organization Department
  • Organization DUNS
  • Organization City
    PLYMOUTH MEETING
  • Organization State
    PA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    19462
  • Organization District
    UNITED STATES